Tag - Hepion Pharmaceuticals

Markets

Roth starts Hepion Pharma at buy; PT $9

Roth Capital Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $9 price target. The stock closed at $2.95 on Nov. 6. “Hepion brings a laser focus on liver disease, combined with...

November 7, 2019

Executive Moves

Hepion appoints renowned liver disease expert, Dr. Stephen Harrison, as consultant medical director

Stephen Harrison Hepion Pharmaceuticals (NASDAQ:HEPA) appointed world-renowned Dr. Stephen Harrison as consultant medical director. Dr. Harrison is a peer-reviewer for more than 20 medical journals. He is...

October 10, 2019

Developments

Hepion Pharma doses first HBV patient in 28-day study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) has dosed the first hepatitis B virus (HBV) patient in a 28-day multiple ascending dose clinical trial of CRV431. The trial will assess the safety, tolerability and pharmacokinetics...

August 14, 2019

Executive Moves

Hepion Pharma names renowned liver expert, Dr. Stephen Harrison, to its SAB

Stephen Harrison Dr. Stephen Harrison, a leading authority on liver diseases, has joined the scientific advisory board (SAB) of Hepion Pharmaceuticals (NASDAQ:HEPA). Dr. Harrison is a visiting professor of hepatology at...

August 7, 2019

Tag - Hepion Pharmaceuticals

Roth starts Hepion Pharma at buy; PT $9

Hepion appoints renowned liver disease expert, Dr. Stephen Harrison, as consultant medical director

Hepion Pharma doses first HBV patient in 28-day study of CRV431

Hepion Pharma names renowned liver expert, Dr. Stephen Harrison, to its SAB

General

More